Physician profile
Juan E Bahamon
NPI 1548376130
$8,098.44
in general payments reported to CMS, 2019-2025
39 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,674 · 2020: $1,947 · 2021: $168 · 2023: $54.90 · 2024: $25.51 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222 · Travel and Lodging: $86.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.05 |
| Travel and Lodging | $86.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,139.68 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $680.17 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $589.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $571.52 | 2019-2020 | |
| Biogen, INC. | $533.49 | 2019-2020 | |
| Genzyme Corporation | $424.28 | 2019-2023 | |
| Genentech USA, INC. | $375.96 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $255.39 | 2019-2020 | |
| Livanova USA, INC. | $247.90 | 2019-2021 | |
| Mdd US Operations, LLC | $246.74 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $246.17 | 2019-2020 | |
| Ucb, INC. | $244.81 | 2019-2020 | |
| Amgen INC. | $244.35 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $237.54 | 2019-2020 | |
| Medtronic, INC. | $228.52 | 2025 | Turbohawk |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Bahamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.